Liquid biopsy company GRAIL, Inc. filed with the US Securities and Exchange Commission to raise up to $100m in an initial public offering with plans to launch its multi-cancer early detection blood test, Galleri, in 2021 as a laboratory-developed test (LDT), the company announced on 9 September.
Morgan Stanley, Goldman Sachs & Co. LLC and BofA Securities will act as lead underwriting firms for the proposed offering, Grail said